ERBB3 and neoplasm: Taken in conjunction with the present findings it is possible that HRGβ1/erbB3-mediated signalling in the presence of trastuzumab and gefitinib may maintain cell growth and promote enhanced invasive features within the tumour cells, potentially explaining the reduced time to progression observed in patients receiving this treatment regime.